ReviewThe British journal of radiology2014
An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.
Review in The British journal of radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Trial
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Matairesinol Targets Lipid Metabolism Reprogramming in AR-Independent Prostate Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Review
- Prediction of prostate tumour hypoxia using pre-treatment MRI-derived radiomics: preliminary findings.La Radiologia medica · 2023Article
- Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.Oncogene · 2023Article
- A GdWMolecules (Basel, Switzerland) · 2021Article
- Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts.Cancers · 2021Article
- HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition.Frontiers in cell and developmental biology · 2021Article
- Bad neighbours: hypoxia and genomic instability in prostate cancer.The British journal of radiology · 2020Review
- Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells.Clinical epigenetics · 2020Article
- Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study.The British journal of radiology · 2019Article
- Review
- Predicting Treatment Outcomes: The Case for Hypoxia Gene Signatures.EBioMedicine · 2018Article
- Atorvastatin enhances radiosensitivity in hypoxia-induced prostate cancer cells related with HIF-1α inhibition.Bioscience reports · 2017Article
- The changing paradigm of tumour response to irradiation.The British journal of radiology · 2017Review
- Molecular mechanisms of hypoxia in cancer.Clinical and translational imaging · 2017Review
- Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.Cancer letters · 2016Review
- Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response.NPJ genomic medicine · 2016Article
- Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life.Frontiers in oncology · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (CaP) is the most commonly diagnosed malignancy in males in the Western world with one in six males diagnosed in their lifetime. Current clinical prognostication groupings use pathologic Gleason score, pre-treatment prostatic-specific antigen and Union for International Cancer Control-TNM staging to place patients with localized CaP into low-, intermediate- and high-risk categories. These categories represent an increasing risk of biochemical failure and CaP-specific mortality rates, they also reflect the need for increasing treatment intensity and justification for increased side effects. In this article, we point out that 30-50% of patients will still fail image-guided radiotherapy or surgery despite the judicious use of clinical risk categories owing to interpatient heterogeneity in treatment response. To improve treatment individualization, better predictors of prognosis and radiotherapy treatment response are needed to triage patients to bespoke and intensified CaP treatment protocols. These should include the use of pre-treatment genomic tests based on DNA or RNA indices and/or assays that reflect cancer metabolism, such as hypoxia assays, to define patient-specific CaP progression and aggression. More importantly, it is argued that these novel prognostic assays could be even more useful if combined together to drive forward precision cancer medicine for localized CaP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.